Lunit Supplies AI Solutions to 11 Local Health Authorities in Italy

Supplying AI Cancer Diagnostic Solutions
to 11 Italian ASLs Covering 14% of the Population

Medical artificial intelligence (AI) company Lunit announced on August 26 that it has supplied its AI cancer diagnostic solutions to 11 local health authorities (Azienda Sanitaria Locale, ASL) in Italy.

Dr. Claudia Weiss, head of the breast cancer screening program in Treviso, Italy, is analyzing mammography images using Lunit AI breast cancer diagnostic solution 'Lunit Insight MMG'. Lunit

The 11 ASLs are responsible for a population of approximately 8.5 million, which accounts for about 14% of Italy's total population of 58.9 million. ASLs are key organizations that operate public healthcare services on a regional basis in Italy. Each ASL manages multiple medical institutions within its jurisdiction-including hospitals, health centers, and diagnostic centers-providing healthcare services to local residents.

The ASLs in Italy that have adopted Lunit's solutions include five in the Lazio region, which covers the Rome metropolitan area; three in the Lombardia region, which includes the Milan metropolitan area; two in the Veneto region, which covers the Venice metropolitan area; and one in the Umbria region in central Italy. These institutions encompass numerous hospitals and health centers within their regions and are considered strategic hubs in the Italian healthcare system, handling high medical demand and patient volumes.

With this contract, Lunit has expanded its business portfolio to cover all of Europe, entering Southern Europe along the Mediterranean coast in addition to its previous presence in Western, Northern, and Eastern Europe. The products supplied are two AI imaging diagnostic solutions: 'Lunit Insight CXR' and 'Lunit Insight MMG.' These solutions have been integrated into the imaging diagnostic systems of the respective ASLs and are currently supporting cancer diagnosis in real clinical settings. The fact that Lunit's solutions have been practically implemented in Italy's national healthcare infrastructure, which is centered on public healthcare, is particularly significant.

This supply was made possible by Lunit forming partnerships with local imaging device distributors and successfully managing the entire process from bidding to solution delivery. Lunit plans to further strengthen its presence in the European B2G (business-to-government) medical market by pursuing a strategy that combines sales through such partnerships with direct sales.

Seo Bumseok, CEO of Lunit, stated, "Lunit is currently one of the fastest-growing companies in the European public healthcare sector, and we will continue to contribute to improving universal healthcare accessibility in even more countries. Building on our achievements across all regions, from Northern to Southern Europe, we will further solidify our position as a global medical AI company."

Meanwhile, Lunit expects to sign additional contracts with five more ASLs in central and northern Italy by the end of this year. If these contracts are included, Lunit's AI cancer diagnostic solutions will cover a population of approximately 12.3 million, which is about 20% of Italy's total population.